Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - TIANYIN PHARMACEUTICAL CO., INC. | f8k111512_tianyin.htm |
| EX-99.2 - SCRIPT OF CONFERENCE CALL ON NOVEMBER 15, 2012 - TIANYIN PHARMACEUTICAL CO., INC. | f8k111512ex99ii_tianyin.htm |
Exhibit 99.1
TPI Reports First Quarter Fiscal Year 2013 Financial Results
CHENGDU, China, Nov. 15, 2012 -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for first quarter of the fiscal year 2013.
First Quarter of Fiscal Year 2013 Ended September 30, 2012 Financial Highlights:
|
●
|
Revenue was $16.0 million compared with $17.5 million for the quarter ended September 30, 2011;
|
|
●
|
Operating income was $2.2 million, compared with $2.1 million for the quarter ended September 30, 2011;
|
|
●
|
Net Income was $1.5 million compared with $1.5 million for the quarter ended September 30, 2011;
|
|
●
|
Earnings per share of $0.05 per basic share, and $0.05 per diluted share, compared with $0.05 per basic share, or $0.05 per diluted share for the quarter ended September 30, 2011;
|
|
●
|
Cash and cash equivalents totaled $37.5 million on September 30, 2012; Operating cash flow for the quarter ended September 30, 2012 was $0.5 million, compared with $3.6 million for the quarter ended September 30, 2011.
|
Comparison of results for the quarters ended September 30, 2012 and 2011:
|
Quarters
Ended September 30,
|
||||||||
|
2012
|
2011
|
|||||||
|
(In millions)
|
||||||||
|
Sales
|
$
|
16.0
|
$
|
17.5
|
||||
|
Cost of sales
|
$
|
9.7
|
$
|
11.7
|
||||
|
Gross profit
|
$
|
6.2
|
$
|
5.9
|
||||
|
Total operating expenses
|
$
|
4.1
|
$
|
3.7
|
||||
|
Provision for income taxes
|
$
|
0.6
|
$
|
2.1
|
||||
|
Net income
|
$
|
1.5
|
$
|
1.5
|
||||
Sales for the quarter ended September 30, 2012 was $16.0 million, a decrease of 8.6% as compared to $17.5 million for the quarter ended September 30, 2011. The sales decrease was predominately the result of continuous generic pricing pressure amid healthcare reform further augmented by continued restrictive government policies to prioritize the Essential Drug List (EDL) drug sales. This simultaneously reduced the sales of our higher margin generic pharmaceuticals. However, on a positive note we did observe a stabilization of the pricing trends from a year earlier while comparing the revenue for the quarter ended September 30, 2011 with the respective period in 2010.
Our top five product sales are: Gingko mihuan oral liquid (GMOL) for stroke and cardiovascular disorders: $6.3 million; Mycophenolate mofetil capsules (MM) for renal transplant: $1.8 million; Azithromycin tablets (AZI) for infection: $0.95 million; Qingre jiedu oral liquid (QR): $0.94 million and Qianlie Shule capsules (QS) for prostate conditions: $0.42 million. These products totaled $10.4 million in sales, representing 62% of the quarterly revenue. The previous two core products Apu Shuangxin Benorylate Granules (Apu) and Xuelian Chongcao (XLCC) which are not covered by EDL or National Reimbursement List (NRL), have not reached the level to be included in the top five products mainly caused by the healthcare reform regulations that favor EDL and NRL drugs. Compared with a year earlier, the total core product sales have risen significantly from the $5.6 million for the quarter ended September 30, 2011 mainly due to the significant rise of GMOL sales: a 117% growth from $2.9 million for the quarter ended September 30, 2011. The strong sale momentum in GMOL, in our opinion, is a result of the inclusion of GMOL in a number of Provincial EDL such as the provinces of Henan and Shandong and the City of Chongqing. We expect the trend to continue for the remainder of fiscal year 2013.
Cost of Sales for the quarter ended September 30, 2012 was $9.7 million or 60.6% of sales, as compared to $11.7 million or 66.9% of sales for the quarter ended September 30, 2011. The percentage decrease in our cost of sales from the previous period was predominately attributable to a greater mix of higher margin products. While our market analysis has not yet fully affirmed a trend of continuous margin improvement we do believe that present sales data supports a flattening and slightly positive trend in our Cost of Sales. The contribution from our distribution business through Tianyin Medicine Trading (TMT) amounted to $3.9 million at 11% gross margin.
Gross Margin for the quarter ended September 30, 2012 was 39.1% as compared to 33.4% for the quarter ended September 30, 2011. As discussed above in the segment of costs of sales, our gross margin improved predominately as a result of a greater mix of higher margin products being sold during the period supported by a leveling off of negative pricing pressures in our lower margin generic portfolio. We expect that our overall gross margin in the near term, on a quarter to quarter comparison basis will likely improve from last year based upon continued improvement of our portfolio mix of higher margin products.
Operating Expenses were $4.1 million for the quarter ended September 30, 2012, as compared to $3.7 million for the quarter ended September 30, 2011. The increase in operating expenses was mainly associated with an increase in sales and marketing costs.
Net Income was $1.5 million with a net margin of 9.6% for the quarter ended September 30, 2012, as compared to net income of $1.5 million with net margin of 8.7% for the quarter ended September 30, 2011. This was predominately a direct result of improvements in our gross margins.
Diluted earnings per share for the quarter ended September 30, 2012 were $0.05 based on 29.3 million shares compared with the earnings of $0.05 per diluted share for the quarter ended September 30, 2011, based on 29.4 million shares.
Balance Sheet and Cash Flow
As of September 30, 2012, we had working capital totaling $44.2 million, including cash and cash equivalents of $37.5 million. Net cash generated in operating activities was $0.48 million for the three months ended September 30, 2012 as compared with net cash generated from operating activities as $3.6 million for the three months ended September 30, 2011. The net decrease in operating cash flow was predominately the result of; 1) an increase in the payment of trade notes payable of $3.1 million that was due this quarter, 2) a decrease of inventory of $1.4 million, and 3) an increase of advance from customer of $1.1 million. We believe that TPI is adequately funded to meet all of our working capital and capital expenditure needs for fiscal year 2013.
2
Business Development & Outlook
R&D for additional indications of flagship product Gingko Mihuan (GMOL)
Our flagship product Gingko Mihuan Oral Liquid (GMOL, SFDA certification number: H20013079; patent number: 20061007800225) contributes approximately 39% to our total revenue. Clinical application and information gathered from our physicians showed that in addition to our approved indication for GMOL: cardiovascular disorders, coronary heart disease and cerebral ischemic attack including strokes, off-label use of GMOL have been indicated in hepatic diseases and ophthalmological diseases. The validity of these observations is currently being investigated.
Jiangchuan Macrolide Project (JCM)
TPI has completed the 240-ton JCM facility for the R&D, manufacturing and sale of API and chemical intermediates of macrolide antibiotics. In January 2012, JCM was approved for its GMP certification designated as "CHUAN M0799," which is valid for the period of December 31, 2011 until December 31, 2015. The JCM underwent efficiency improvement and calibration for large scale production for the initial three months of operation. By July 2012, JCM has started producing macrolide API for TPI's production of Azithromycin Dispersible Tablets (SFDA No: H20074145).
Tianyin Medicine Trading Distribution Business (TMT)
TMT is established to distribute products manufactured by both TPI and other pharmaceutical companies to fuel our expanding sales network as well as to provide synergy to our existing organic product portfolio. TMT has been distributing mainly TPI's own products since its inception in 2009. Since 2010, TPI has signed and later extended distribution contracts with Jiangsu Lianshui Pharmaceutical ("Lianshui") to distribute Lianshui-branded generic injection products including cough suppressant, antibiotics, anti-inflammatory medicines and other healthcare indications. On average, TMT distribution revenue contributed approximately $3-5 million sales per quarter to our total revenue.
Pre-extraction and formulation plant development at Qionglai Facility (QLF)
In preparation for the new Good Manufacturing Practice (GMP) standards stipulated by the PRC government in early 2011, TPI initiated the process of optimizing the manufacturing facilities and production lines in compliance with the new GMP standards by 2013. Concurrently, the city of Chengdu has re-designated various industrial parks for particular industries such as automobile, biotechnologies, pharmaceuticals and chemical engineering. As a consequence, TPI's current manufacturing facility at the Longquan district, east of Chengdu, which is designated for use by the automotive industry, is scheduled to be relocated to Qionglai city, south of Chengdu, which is designated for use by the pharmaceutical industry. The Qionglai facility (QLF) is approximately 18 miles from the Company's recently completed JCM facility. The proposed relocation project also includes our TCM pre-extraction plant, which is located near the center of city of Chengdu, a rapidly expanding residential area.
3
The QLF is estimated to be 80 mu or approximately 13 acres. Both pre-extraction plant and the formulation plant are to be relocated. The combined QLF plant, designed and constructed according to the latest GMP standards, is expected to relieve the current capacity saturation at TPI's facilities. The re-location and construction cost is estimated at $25 million for Phase I which, when completed in the end of calendar year 2012, will expand the current capacity by 30%. For Phase II of the QLF project, an additional $10 million in capital investment may be made to double the current capacity by calendar year 2013 if demand is required.
Fiscal Year 2013 Guidance
We are assuming that continued pricing pressures in our marketplace will remain constant for the upcoming year as we expect further reforms to be undertaken in the healthcare marketplace in China. This will continue to put pressure on our revenue growth in 2013, but we believe that JCM and TMT distribution business may help us overcome these external pressures and allow us to deliver 2013 revenue growth of approximately 10% to 15%. Therefore, we reiterate our fiscal 2013 revenue projection of approximately $75 to $80 million along with a net margin of approximately 10%.
We believe the following factors will influence the future growth perspectives of our Company: 1) Market expansion and revenue growth of TPI's core product portfolio led by flagship product Gingko Mihuan Oral Liquid (GMOL) and other major products; 2) Ramp up of JCM revenue in the fiscal year 2013; 3) The gradual stabilization of generic sales following the progressive pricing restrictions caused by the ongoing healthcare reform; 4) Steady TMT distribution revenue contribution; and 5) QLF relocation and smooth transition of production capacity.
Management will continue to evaluate the Company's business outlook and communicate any changes on a quarterly basis or as when appropriate.
Conference Call
Senior management of TPI will host its earnings conference call for the first quarter fiscal year 2013 ending September 30, 2012 to be held at 8:30 a.m. ET on Thursday, November 15, 2012.
Interested parties may access the call by dialing 1-877-941-4774 (U.S.) or 1-480-629-9760 (International).
The conference ID is 4572569. It is advisable to dial in approximately 5 minutes prior to the start of the call.
A replay will be available by calling 1-877-870-5176 (U.S.) or 1-858-384-5517
From: 11/15/2012 @ 11:30 am E.T. To: 11/29/2012 @ 11:59 pm E.T.
Replay Pin Number: 4572569
4
This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://public.viavid.com/index.php?id=102266
About TPI
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications.
For more information about TPI, please visit: http://www.tianyinpharma.com.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please contact:
Investors Contact: ir@tpi.asia
Web: http://www.tianyinpharma.com
Tel: +86-28-8551-6696 (Chengdu, China)
+86 134-36-550011 (China)
Address:
23rd Floor Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China
5
|
TIANYIN PHARMACEUTICAL CO., INC.
|
|
Consolidated Balance Sheets
|
|
September 30,
|
June 30,
|
|||||||
|
2012
|
2012
|
|||||||
|
Assets
|
(Unaudited)
|
|||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
37,538,365
|
$
|
35,152,295
|
||||
|
Restricted cash
|
1,583,000
|
3,534,550
|
||||||
|
Accounts receivable, net of allowance for doubtful accounts of $113,719
|
||||||||
|
and $113,862 at September 30, 2012 and June 30, 2012, respectively
|
10,264,113
|
11,272,367
|
||||||
|
Inventory
|
6,432,893
|
5,863,013
|
||||||
|
Advance payments
|
-
|
642,075
|
||||||
|
Other current assets
|
475,866
|
436,664
|
||||||
|
Total current assets
|
56,294,237
|
56,900,964
|
||||||
|
Property and equipment, net
|
26,040,538
|
26,458,349
|
||||||
|
Intangibles, net
|
20,732,243
|
20,958,226
|
||||||
|
Total assets
|
$
|
103,067,018
|
$
|
104,317,539
|
||||
|
Liabilities
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable and accrued expenses
|
$
|
1,487,623
|
$
|
1,586,151
|
||||
|
Accounts payable – construction related
|
410,899
|
740,832
|
||||||
|
Short-term bank loans
|
6,015,400
|
6,023,000
|
||||||
|
Trade notes payable
|
1,583,000
|
4,675,750
|
||||||
|
Advances from customer
|
1,139,760
|
-
|
||||||
|
Income tax payable
|
583,307
|
804,595
|
||||||
|
Other taxes payable
|
480,104
|
500,782
|
||||||
|
Other current liabilities
|
425,931
|
466,982
|
||||||
|
Total current liabilities
|
12,126,024
|
14,798,092
|
||||||
|
Total liabilities
|
12,126,024
|
14,798,092
|
||||||
|
Equity
|
||||||||
|
Stockholders' equity:
|
||||||||
|
Common stock, $0.001 par value, 50,000,000 shares authorized,
|
||||||||
|
29,332,791 shares issued and outstanding at September 30, 2012
|
||||||||
|
and June 30, 2012
|
29,446
|
29,446
|
||||||
|
Additional paid-in capital
|
30,117,997
|
30,104,902
|
||||||
|
Treasury stock
|
(135,925
|
) |
(135,925
|
) | ||||
|
Statutory reserve
|
6,120,143
|
6,120,143
|
||||||
|
Retained earnings
|
46,563,946
|
45,022,329
|
||||||
|
Accumulated other comprehensive income
|
7,988,385
|
8,100,526
|
||||||
|
Total stockholders' equity
|
90,683,992
|
89,241,421
|
||||||
|
Noncontrolling interest
|
257,002
|
278,026
|
||||||
|
Total equity
|
90,940,994
|
89,519,447
|
||||||
|
Total liabilities and equity
|
$
|
103,067,018
|
$
|
104,317,539
|
||||
6
|
TIANYIN PHARMACEUTICAL CO., INC.
|
||||||||
|
Consolidated Statements of Operations and Comprehensive Income
|
||||||||
|
(Unaudited)
|
||||||||
|
For the Three Months Ended
|
||||||||
|
September 30,
|
||||||||
|
2012
|
2011
|
|||||||
|
Sales
|
$
|
15,971,697
|
$
|
17,528,578
|
||||
|
Cost of sales
|
9,727,993
|
11,675,529
|
||||||
|
Gross profit
|
6,243,704
|
5,853,049
|
||||||
|
Operating expenses
|
||||||||
|
Selling expenses
|
2,761,438
|
2,477,326
|
||||||
|
General and administrative expenses
|
1,121,533
|
1,019,122
|
||||||
|
Research and development
|
215,930
|
210,715
|
||||||
|
Total operating expenses
|
4,098,901
|
3,707,163
|
||||||
|
Income from operations
|
2,144,803
|
2,145,886
|
||||||
|
Other income (expenses):
|
||||||||
|
Interest income
|
67,602
|
34,961
|
||||||
|
Interest expense
|
(108,404
|
) |
(49,845
|
) | ||||
|
Other income
|
-
|
(4,718
|
) | |||||
|
Total other expenses
|
(40,802
|
) |
(19,602
|
) | ||||
|
Income before provision for income taxes
|
2,104,001
|
2,126,284
|
||||||
|
Provision for income taxes
|
583,048
|
619,067
|
||||||
|
Net income
|
1,520,953
|
1,507,217
|
||||||
|
Less: net income attributable to noncontrolling interest
|
(20,664
|
) |
(18,023
|
) | ||||
|
Net income attributable to Tianyin Pharmaceutical Co., Inc.
|
$
|
1,541,617
|
$
|
1,525,240
|
||||
|
Basic earnings per share
|
$
|
0.05
|
$
|
0.05
|
||||
|
Diluted earnings per share
|
$
|
0.05
|
$
|
0.05
|
||||
|
Weighted average number of common shares outstanding:
|
||||||||
|
Basic
|
29,332,791
|
29,396,276
|
||||||
|
Diluted
|
29,332,791
|
29,396,276
|
||||||
7
|
TIANYIN PHARMACEUTICAL CO., INC.
|
||||||||
|
Consolidated Statements of Comprehensive Income
|
||||||||
|
(Unaudited)
|
|
For the Three Months Ended
|
||||||||
|
September 30,
|
||||||||
|
2012
|
2011
|
|||||||
|
Net income
|
$
|
1,520,953
|
$
|
1,507,217
|
||||
|
Other comprehensive income (loss)
|
||||||||
|
Foreign currency translation adjustment
|
(112,500
|
) |
947,507
|
|||||
|
Total other comprehensive income (loss)
|
(112,500
|
) |
947,507
|
|||||
|
Total Comprehensive income
|
1,408,453
|
2,454,724
|
||||||
|
Less: Comprehensive income (loss) attributable to the noncontrolling interest
|
(21,024
|
) |
237,404
|
|||||
|
Comprehensive income attributable to
|
||||||||
|
Tianyin Pharmaceutical Co., Inc.
|
$
|
1,429,477
|
$
|
2,217,320
|
||||
8
|
TIANYIN PHARMACEUTICAL CO., INC.
|
||||||||
|
Consolidated Statements of Cash Flows
|
||||||||
|
(Unaudited)
|
||||||||
|
For the Three Months Ended
|
||||||||
|
September 30,
|
||||||||
|
2012
|
2011
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net Income
|
$
|
1,520,953
|
$
|
1,507,217
|
||||
|
Adjustments to reconcile net income to net cash
|
||||||||
|
provided by (used in) operating activities:
|
||||||||
|
Depreciation and amortization
|
583,704
|
286,668
|
||||||
|
Share-based payments
|
13,095
|
|||||||
|
Provision for bad debts
|
-
|
43,558
|
||||||
|
Changes in current assets and current liabilities:
|
||||||||
|
Accounts receivable
|
993,591
|
699,626
|
||||||
|
Inventory
|
(577,022
|
) |
820,036
|
|||||
|
Advance payments
|
640,981
|
581,122
|
||||||
|
Other current assets
|
(39,736
|
) |
(63,523
|
) | ||||
|
Accounts payable and accrued expenses
|
(96,477
|
) |
828,517
|
|||||
|
Accounts payable – construction related
|
(328,853
|
) |
(238,357
|
) | ||||
|
Trade notes payable
|
(3,085,485
|
) |
-
|
|||||
|
Advances from customer
|
1,139,256
|
-
|
||||||
|
Income tax payable
|
(220,175
|
) |
(368,238
|
) | ||||
|
Other taxes payable
|
(20,037
|
) |
(342,478
|
) | ||||
|
Other current liabilities
|
(40,444
|
) |
(129,363
|
) | ||||
|
Total adjustments
|
(1,037,602
|
) |
2,117,568
|
|||||
|
Net cash provided by operating activities
|
483,351
|
3,624,785
|
||||||
|
Cash flows from investing activities:
|
||||||||
|
Addition to property and equipment
|
-
|
(113,819
|
) | |||||
|
Additions to intangible assets – approved drugs
|
-
|
(765,282
|
) | |||||
|
Additions to intangible assets – land use right
|
-
|
(1,815,804
|
) | |||||
|
Net cash used in investing activities
|
-
|
(2,694,905
|
) | |||||
|
Cash flows from financing activities:
|
||||||||
|
Restricted cash
|
1,946,229
|
(1,530,564
|
) | |||||
|
Proceeds from short-term bank loans
|
-
|
1,561,800
|
||||||
|
Net cash provided by financing activities
|
1,946,229
|
31,236
|
||||||
|
Effect of foreign currency translation on cash
|
(43,510
|
) |
621,270
|
|||||
|
Net increase in cash and cash equivalents
|
2,386,070
|
1,582,386
|
||||||
|
Cash and cash equivalents – beginning
|
35,152,295
|
31,724,906
|
||||||
|
Cash and cash equivalents – ending
|
$
|
37,538,365
|
$
|
33,307,292
|
||||
|
Supplemental disclosures of cash activities
|
||||||||
|
Cash paid for interest
|
$
|
108,404
|
$
|
49,845
|
||||
|
Cash paid for income taxes
|
$
|
803,579
|
$
|
987,304
|
||||
9